Skip to content
10-Q

Quarterly Report

Guardant Health, Inc. GH

0001576280-26-000026

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 132.6M sh
Shares Diluted Q1 2026 · Mar 31, 2026 131.27M sh
Shares Diluted Q1 2026 · Mar 31, 2025 123.87M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $0
Stock Repurchased Q1 2026 · Mar 31, 2025 $45.01M
Capex Q1 2026 · Mar 31, 2026 $5.58M
Capex Q1 2026 · Mar 31, 2025 $4.46M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$65.62M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$62.69M
Long Term Debt Q1 2026 · Mar 31, 2026 $1.5B
Long Term Debt Q1 2026 · Dec 31, 2025 $1.5B
Cash And Equivalents Q1 2026 · Mar 31, 2026 $989.29M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $378.2M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $698.57M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$181.07M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$99.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$250.79M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$139.65M
Current Liabilities Q1 2026 · Mar 31, 2026 $292.15M
Current Liabilities Q1 2026 · Dec 31, 2025 $302.73M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.1B
Total Liabilities Q1 2026 · Dec 31, 2025 $2.11B
Current Assets Q1 2026 · Mar 31, 2026 $1.37B
Current Assets Q1 2026 · Dec 31, 2025 $1.47B
Total Assets Q1 2026 · Mar 31, 2026 $1.92B
Total Assets Q1 2026 · Dec 31, 2025 $2.01B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.85
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.77
Eps Basic Q1 2026 · Mar 31, 2026 −$0.85
Eps Basic Q1 2026 · Mar 31, 2025 −$0.77
Sga Expense Q1 2026 · Mar 31, 2026 $57.93M
Sga Expense Q1 2026 · Mar 31, 2025 $46.95M
Rd Expense Q1 2026 · Mar 31, 2026 $91.04M
Rd Expense Q1 2026 · Mar 31, 2025 $88.52M
Net Income Q1 2026 · Mar 31, 2026 −$112.08M
Net Income Q1 2026 · Mar 31, 2025 −$95.16M
Operating Income Q1 2026 · Mar 31, 2026 −$121.35M
Operating Income Q1 2026 · Mar 31, 2025 −$111.04M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $104.92M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $74.72M
Revenue Q1 2026 · Mar 31, 2026 $301.67M
Revenue Q1 2026 · Mar 31, 2025 $203.47M